New PET Imaging Agent for Recurrent Prostate Cancer Approved by US FDA
|
By MedImaging International staff writers Posted on 06 Jun 2016 |
|
Image: The newly approved PET imaging agent Fluciclovine (18F) anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) is a synthetic amino acid (Photo courtesy of Blue Earth Diagnostics).
The US Food and Drug Administration (FDA) has approved the first PET imaging molecular imaging agent for use in patients who have suspected recurrent prostate cancer.
The agent is indicated for use in Positron Emission Tomography (PET) imaging, is administered by injection, and can help clinicians identify suspected recurrence of prostate cancer in men. The agent is intended for patients with elevated levels of Prostate Specific Antigen (PSA) in their blood following prior treatment. Primary prostate cancer can be treated successfully, but recurrence can occur in nearly 33% of patients, and is detected by testing the PSA levels in the blood.
Blue Earth Diagnostics (BED; Oxford, UK) licensed the agent, Axumin (fluciclovine F 18), from GE Healthcare (Chalfont St Giles, Buckinghamshire, UK), and is investigating the molecule for other potential cancer indications, such as glioma. The FDA-approval follows two successful clinical studies of Axumin.
Brian F. Chapin, MD, assistant professor, Department of Urology, the University of Texas MD Anderson Cancer Center, said, “Approximately 180,000 new cases of prostate cancer are expected to be diagnosed in the United States in 2016, and between 20 to 30 percent of patients receiving primary therapy will develop biochemically recurrent disease. There is a need for clinical imaging techniques that can detect and localize suspected recurrent prostate cancer to facilitate the most appropriate patient management decision. Current commercially available imaging techniques have some limitations in terms of identifying recurrent tumors, which may impact subsequent patient management decisions. Additionally, many patient care options for men with suspected recurrent prostate cancer have uncertain benefits that may not justify the risk of side effects. New imaging procedures that can provide reliable information can be useful tools for effective patient management and care.”
Related Links:
Blue Earth Diagnostics
GE Healthcare
The agent is indicated for use in Positron Emission Tomography (PET) imaging, is administered by injection, and can help clinicians identify suspected recurrence of prostate cancer in men. The agent is intended for patients with elevated levels of Prostate Specific Antigen (PSA) in their blood following prior treatment. Primary prostate cancer can be treated successfully, but recurrence can occur in nearly 33% of patients, and is detected by testing the PSA levels in the blood.
Blue Earth Diagnostics (BED; Oxford, UK) licensed the agent, Axumin (fluciclovine F 18), from GE Healthcare (Chalfont St Giles, Buckinghamshire, UK), and is investigating the molecule for other potential cancer indications, such as glioma. The FDA-approval follows two successful clinical studies of Axumin.
Brian F. Chapin, MD, assistant professor, Department of Urology, the University of Texas MD Anderson Cancer Center, said, “Approximately 180,000 new cases of prostate cancer are expected to be diagnosed in the United States in 2016, and between 20 to 30 percent of patients receiving primary therapy will develop biochemically recurrent disease. There is a need for clinical imaging techniques that can detect and localize suspected recurrent prostate cancer to facilitate the most appropriate patient management decision. Current commercially available imaging techniques have some limitations in terms of identifying recurrent tumors, which may impact subsequent patient management decisions. Additionally, many patient care options for men with suspected recurrent prostate cancer have uncertain benefits that may not justify the risk of side effects. New imaging procedures that can provide reliable information can be useful tools for effective patient management and care.”
Related Links:
Blue Earth Diagnostics
GE Healthcare
Gold Member
Electrode Solution and Skin Prep
Signaspray
Gold Member
Ultrasound System
FUTUS LE
Digital Radiography System
DuraDiagnost F30
Gold Member
CR Reader
FCR PRIMA II
Latest Nuclear Medicine News
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease
- Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
MRI
view channel
PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale to assess potential prostate cancer in MR images. PI-RADS category 3 which offers an unclear suggestion of clinically significant... Read more
Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
Essential tremor, often called familial, idiopathic, or benign tremor, leads to uncontrollable shaking that significantly affects a person’s life. When traditional medications do not alleviate symptoms,... Read more
Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
Prostate cancer ranks as the most prevalent cancer among men. Over the last decade, the introduction of MRI scans has significantly transformed the diagnosis process, marking the most substantial advancement... Read more
Ultrasound
view channel
Deep Learning Advances Super-Resolution Ultrasound Imaging
Ultrasound localization microscopy (ULM) is an advanced imaging technique that offers high-resolution visualization of microvascular structures. It employs microbubbles, FDA-approved contrast agents, injected... Read more
Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
Biofilms, formed by bacteria aggregating into dense communities for protection against harsh environmental conditions, are a significant contributor to various infectious diseases. Biofilms frequently... Read more
General/Advanced Imaging
view channel
New AI Method Captures Uncertainty in Medical Images
In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more.jpg "Image: CT coronary angiography for diagnosing coronary artery disease offers advantages over other diagnostic tests (Photo courtesy of 123RF)")
CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
Coronary artery disease (CAD), one of the leading causes of death worldwide, involves the narrowing of coronary arteries due to atherosclerosis, resulting in insufficient blood flow to the heart muscle.... Read more
Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
Alzheimer's disease (AD), a condition marked by cognitive decline and the presence of beta-amyloid (Aβ) plaques and neurofibrillary tangles in the brain, poses diagnostic challenges. Amyloid positron emission... Read more.jpg "Image: Exemplary illustration of the labeling and segmentation process (Photo courtesy of TUM)")
CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
The rise in the aging population is expected to result in a corresponding increase in the prevalence of vertebral fractures which can cause back pain or neurologic compromise, leading to impaired function... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
